Facebook fracas yields new Merck followers; Watson nabs FDA approval for Yaz copy;

 @FiercePharma: Large-vial woes in Las Vegas: Surgeon sues Allergan over Botox vials that 'encourage reuse,' after Teva/propofol trials. News | Follow @FiercePharma

> Merck & Co. ($MRK) has garnered "hundreds" of new followers, thanks to a public tussle between Merck KGaA and Facebook over the rights to the www.facebook.com/Merck URL. Story

> AstraZeneca ($AZN) and Bristol-Myers Squibb's ($BMY) combination diabetes remedy Komboglyze has won approval from European regulators. News

> Watson Pharmaceuticals ($WPI) won has FDA approval for its version of Bayer's Yaz contraceptive pill, but Bayer is suing Watson for patent infringement. Article

> Indian officials have ordered Sanofi ($SNY) to pay 650 crore rupees, or about $125 million, in capital gains tax related to its buyout of vaccine maker Shantha Biotech. Sanofi, however, maintains it's not liable for the tax. Story

> Perrigo won FDA approval for a generic version of the over-the-counter decongestant Mucinex. Report

> Swiss drugmaker Naari ordered Nebraska officials to return a drug purchased for use in executions, saying it was "wrongfully diverted" to the state by a middleman. News

> Taro Pharmaceutical Industries said board member Ilan Levitech has resigned due to increased time commitments required for the position. More

> Novo Nordisk obtained a €650 million, 5-year revolving credit facility primarily to refinance expiring credit. Report

> Cognizant inked a deal to provide biostatistical and medical reporting services to AstraZeneca ($AZN). Article

Biotech News

 @FierceBiotech: It looks like bone. It feels like bone. For the most part, it acts like bone. And it came off an inkjet printer. Story | Follow @FierceBiotech

 @RyanMFierce: Idera ($IDRA) has rights to one of its TLR drugs, but no pharma partner in German Merck to help fund it. Release | Follow @RyanMFierce

 @MaureenFierce: Swiss pharmaceutical company wants Nebraska to return drug to be used in lethal injection. News | Follow @MaureenFierce

> Pfizer targets miniblockbuster prospects as Lipitor patent expires. Article

> GSK shakes up R&D units during high-profile review. More

Medical Device News

> Boston Sci wins FDA nod for heart failure devices. Item

> QIAGEN to cut up to 10% of workforce. News

> AcuFocus rakes in $65M in funding. Story

Drug Delivery News

> FDA pins approval on new formulation of Ambien. Article

> Royal DSM injects delivery tech into scar-reduction alliance. Story

> Taris advances human testing of bladder pain treatment delivery device. More

Biomarkers News

> A yogurt a day keeps heart disease biomarkers at bay. Item

> Researchers move closer to ADHD imaging biomarker. News

And Finally... Some cancerous tumors may contain factors that inhibit their own growth. Story

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.